eCite Digital Repository
The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia
Citation
Dallmann, R and Weyermann, P and Anklin, C and Boroff, M and Bray-French, K and Cardel, B and Courdier-Fruh, I and Deppe, H and Dubach-Powell, J and Erb, M and Haefeli, RH and Hennebohle, M and Herzner, H and Hufschmid, M and Marks, DL and Nordhoff, S and Papp, M and Rummey, C and Santos, G and Scharer, F and Siendt, H and Soeberdt, M and Sumanovski, LT and Terinek, M and Mondadori, C and Guven, N and Feurer, A, The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia, Journal of Cachexia, Sarcopenia and Muscle, 2, (3) pp. 163-174. ISSN 2190-5991 (2011) [Refereed Article]
![]() | PDF Restricted - Request a copy 289Kb |
Copyright Statement
Copyright Springer, Part of Springer Science+Business Media
Official URL: http://link.springer.com/
DOI: doi:10.1007/s13539-011-0039-1
Abstract
Item Details
Item Type: | Refereed Article |
---|---|
Keywords: | drug development |
Research Division: | Biomedical and Clinical Sciences |
Research Group: | Medical biochemistry and metabolomics |
Research Field: | Metabolic medicine |
Objective Division: | Health |
Objective Group: | Other health |
Objective Field: | Other health not elsewhere classified |
UTAS Author: | Guven, N (Dr Nuri Guven) |
ID Code: | 79266 |
Year Published: | 2011 |
Web of Science® Times Cited: | 32 |
Deposited By: | Pharmacy |
Deposited On: | 2012-08-29 |
Last Modified: | 2017-11-02 |
Downloads: | 0 |
Repository Staff Only: item control page